IRADIMED CEO trust sells 7,500 shares under plan

IRADIMED CORP director and CEO Roger E. Susi reported that the Phillip Susi 2008 Dynasty Trust, an entity associated with him, sold a total of 7,500 shares of common stock in open-market transactions on May 26–27, 2026.

Rhea-AI Filing Summary

IRADIMED CORP director and CEO Roger E. Susi reported that the Phillip Susi 2008 Dynasty Trust, an entity associated with him, sold a total of 7,500 shares of common stock in open-market transactions on May 26–27, 2026.

The reported weighted-average sale prices ranged from about $91.85 to $92.93 per share across four trades. After these sales, the trust continued to hold 2,165,000 shares of IRADIMED common stock indirectly. All transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on November 5, 2025, indicating they were pre-planned rather than discretionary.

Insider Trade Summary 10b5-1

Net Seller: 7,500 shares

Net Sell 4 txns

Insider Susi Roger E.

Role CEO, President, Chairman

Sold 7,500 shs ($691K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,167	$91.85	$199K
Sale	Common Stock	333	$92.61	$31K
Sale	Common Stock	3,111	$91.81	$286K
Sale	Common Stock	1,889	$92.93	$176K

Holdings After Transaction: Common Stock — 2,165,000 shares (Indirect, By Phillip Susi 2008 Dynasty Trust)

Footnotes (5)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $91.35 to $92.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. F3. This transaction was executed in multiple trades at prices ranging from $92.70 to $93.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. F4. This transaction was executed in multiple trades at prices ranging from $91.41 to $92.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. F5. This transaction was executed in multiple trades at prices ranging from $92.54 to $93.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Total shares sold: 7,500 shares Sale price (May 27 trade 1): $92.61 per share Sale price (May 27 trade 2): $91.85 per share +5 more

8 metrics

Total shares sold 7,500 shares Open-market sales on May 26–27, 2026

Sale price (May 27 trade 1) $92.61 per share 333 shares of common stock sold

Sale price (May 27 trade 2) $91.85 per share 2,167 shares of common stock sold

Sale price (May 26 trade 1) $92.93 per share 1,889 shares of common stock sold

Sale price (May 26 trade 2) $91.81 per share 3,111 shares of common stock sold

Shares held after sales 2,165,333 shares Indirect ownership by Phillip Susi 2008 Dynasty Trust

Number of sale transactions 4 transactions All coded as open-market sales (S)

Trading plan adoption date November 5, 2025 Rule 10b5-1 plan governing the reported sales

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale, indirect ownership, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

open-market sale financial

"transaction_action: "open-market sale" with transaction code "S" for common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"ownership_type: "indirect" and nature_of_ownership: "By Phillip Susi 2008 Dynasty Trust""

multiple trades at prices ranging financial

"This transaction was executed in multiple trades at prices ranging from $91.35 to $92.30."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IRADIMED (IRMD) report for Roger E. Susi?

IRADIMED reported that the Phillip Susi 2008 Dynasty Trust, associated with CEO Roger E. Susi, sold 7,500 shares of common stock in open-market trades. These transactions occurred on May 26–27, 2026, under a pre-established Rule 10b5-1 trading plan.

How many IRADIMED (IRMD) shares were sold and at what prices?

The trust sold a total of 7,500 IRADIMED common shares in four trades. Reported weighted-average sale prices were approximately $91.81, $91.85, $92.61 and $92.93 per share, reflecting execution across multiple trades within specified price ranges.

How many IRADIMED (IRMD) shares does the insider-associated trust still hold?

Following these transactions, the Phillip Susi 2008 Dynasty Trust held 2,165,333 IRADIMED common shares indirectly. This figure reflects the post-transaction ownership reported in the Form 4 and shows the trust retains a substantial position after the sales.

Were the recent IRADIMED (IRMD) insider sales pre-planned under Rule 10b5-1?

Yes. A footnote states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2025. Such plans pre-schedule trades, indicating these sales were arranged in advance rather than timed reactively to short-term market developments.

Who executed the IRADIMED (IRMD) stock sales reported in this Form 4?

The sales were executed by the Phillip Susi 2008 Dynasty Trust, which holds IRADIMED shares indirectly for CEO Roger E. Susi. The Form 4 lists ownership as indirect, with the trust named in the nature of ownership for each transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 03:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FLORIDA 32826

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, President, Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		S(1)		3,111	D	$91.81(2)	2,169,389	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	05/26/2026		S(1)		1,889	D	$92.93(3)	2,167,500	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	05/27/2026		S(1)		2,167	D	$91.85(4)	2,165,333	I	By Phillip Susi 2008 Dynasty Trust
Common Stock	05/27/2026		S(1)		333	D	$92.61(5)	2,165,000	I	By Phillip Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.

2. This transaction was executed in multiple trades at prices ranging from $91.35 to $92.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $92.70 to $93.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $91.41 to $92.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $92.54 to $93.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Roger E. Susi	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)